Transgenomic Announces Executive Changes Paul Kinnon Named President, Chief Executive Officer and Director OMAHA, Neb. (

Transgenomic Announces Executive Changes

Paul Kinnon Named President, Chief

Executive Officer and Director

OMAHA, Neb. (Sept 30, 2013) --

Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and

inherited diseases through diagnostic tests as well as clinical and research services, today announced that Paul Kinnon has been

named President, Chief Executive Officer and a Director, replacing Craig J. Tuttle, effective today.

Mr. Kinnon brings over two decades of business

and scientific leadership in the biotechnology and pharmaceutical industries to Transgenomic, with a proven track record of developing

and launching life science products. Most recently, he has provided commercial and strategic consultancy services to a variety

of life science companies and investors, including Transgenomic. With broad experience covering clinical diagnostic, core life

science research and applied markets, his appointment strengthens the executive leadership team and adds significant commercial,

operational, and scientific expertise.

Rodney S. Markin, M.D., Ph.D., Chairman

of Transgenomic commented: "Paul has a demonstrable history of success in building teams, forming strategic partnerships

and leading global organizations. He has also played a pivotal role in the successful growth and development of many innovation-driven

companies. We anticipate that the Board's appointment of Paul as CEO will allow Transgenomic to leverage the Company's

leading assets, talent and business partners." Dr. Markin added: "We thank Craig for his service to the Company and

wish him well in his future endeavors."

"Transgenomic is an exciting

story, with a lot of potential for growth, particularly in the area of innovative genetic testing and services," said

Mr. Kinnon. "We have clear strengths in our tools, technologies, world class clinical and research services, and a

terrific team of motivated people. I look forward to leading the Transgenomic team as we refine and implement strategies

designed to better address our many promising market opportunities and create value for all of our stakeholders."

Before joining Transgenomic, Mr. Kinnon

was President and CEO of ZyGEM Corporation Limited, which he transformed from a local New Zealand reagent firm into a global company

developing breakthrough analytic systems. Mr. Kinnon joined ZyGEM in 2007 from Invitrogen Corp. (now Life Technologies), where he held the positions of Vice President of Global Strategic Alliances and Vice President and General Manager of the

Applied Markets Business Unit. Previously, Mr. Kinnon held business, sales and marketing roles of increasing responsibility at

Guava Technologies, Cellomics, and other life science companies.

About Transgenomic, Inc.

(www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and

inherited diseases. The Company has three complementary business divisions: Clinical Laboratories, Pharmacogenomic Services

and Diagnostic Tools, which provide specialized diagnostic tests, contract research services for drug development, and

equipment, reagents and other consumables for clinical and research applications in molecular testing and cytogenetics.

Forward-Looking Statements

Certain statements in this press release

constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform

Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially

different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements

include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances,

industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in

the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking

statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in

such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred

to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained

in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information

in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information,

including any forward-looking statements, unless required by law.

David Pitts, 212-600-1902

Investor Relations, 402-452-5416